6月2日,再鼎医药宣布,正在进行的全球1a/1b期临床研究的更新数据将在2025年美国临床肿瘤学会(ASCO)年会的壁报展示环节中公布。该研究评估了Delta样配体(DLL3)抗体偶联药物(ADC)zocilurtatug pelitecan(ZL-1310),用于广泛期小细胞肺癌(ES-SCLC)患者。此次公布的数据包括剂量递增部分的更新结果,以及首次公布的来自6个剂量组总共89例入组患者的剂量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.